MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
1.500
+0.050
+3.45%
After Hours: 1.530 +0.03 +2.00% 19:30 09/28 EDT
OPEN
1.450
PREV CLOSE
1.450
HIGH
1.530
LOW
1.430
VOLUME
8.68M
TURNOVER
--
52 WEEK HIGH
2.855
52 WEEK LOW
0.8134
MARKET CAP
261.41M
P/E (TTM)
-2.3459
1D
5D
1M
3M
1Y
5Y
1D
Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 Program
Benzinga · 15h ago
Weekly Report: what happened at PALI last week (0921-0925)?
Weekly Report · 19h ago
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Barchart · 20h ago
Analysts Offer Insights on Healthcare Companies: Palisade Bio (PALI) and Iovance Biotherapeutics (IOVA)
TipRanks · 4d ago
Palisade Bio expands Phase 2b Ascentra-UC with Health Canada CTA clearance
TipRanks · 5d ago
Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis
Benzinga · 5d ago
Palisade Bio Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
Benzinga · 5d ago
More
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Webull offers Palisade Bio Inc stock information, including NASDAQ: PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.